By Brazil Stock Guide — Amil has told employees it is not up for sale, while acknowledging that it remains open to talks with strategic partners, in an effort to contain market noise after reports that private equity funds have shown interest in a potential transaction involving the Brazilian health insurer.
In an internal memo to employees seen by Brazil Stock Guide, Amil’s board of directors said the company “is not for sale.” The message, however, left the door open to the entry of partners or fresh capital to support the company’s investment and expansion plans.
“We want to reinforce that Amil is not for sale. We are, however, open to speaking with strategic partners to strengthen our position and our value proposition for clients, increasing our investment and expansion capacity,” the internal memo said.
The message was sent after reports that Advent and Bain Capital were among the funds interested in a possible transaction involving Amil. According to people familiar with the matter, businessman José Seripieri Filho, known as Júnior, is seeking to preserve control of the company, bring in third-party capital and prepare Amil for a potential IPO once market conditions allow.
Amil said its current leadership team will remain in charge of the company and continue the turnaround process started over the past 30 months. The memo also sought to reassure the group’s roughly 22,000 employees at a time when transaction rumors could affect clients, brokers, healthcare providers and day-to-day operations.
“The current leadership will remain at the helm of the company. We will only return to this subject if there are concrete facts to report,” the memo said.
Seripieri Filho acquired Amil from UnitedHealth Group at the end of 2023, in a transaction that marked the U.S. healthcare group’s exit from Brazil’s health insurance market. The deal was valued at around R$11 billion, of which roughly R$2 billion was paid by the businessman, with the remainder tied to assumed debt.
Since then, Amil has been working to restore profitability, reorganize its healthcare network and reposition its brand in Brazil’s private health insurance market. That process has once again made the company a relevant asset for global funds looking at healthcare opportunities in Brazil, especially in a sector that remains fragmented, pressured by rising medical costs and increasingly focused on scale.
A better-capitalized Amil could increase competition with Hapvida, Rede D’Or/SulAmérica, Bradesco Saúde and other players in a market shaped by regulatory pressure, high medical inflation and growing demand for private health plans.
Leave a Reply